)
Visual24 Oct 2025
The rise of Alphabet
Ikena Oncology (IKNA) investor relations material
Ikena Oncology Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary24 Jul, 2025
Executive summary
Entered into a merger agreement with Inmagene Biopharmaceuticals, with stockholder approval obtained in July 2025; closing expected by end of July, subject to remaining conditions.
Discontinued development of IK-930 and began winding down IK-595 clinical program in July 2025, shifting focus to strategic alternatives and asset divestitures.
Net loss for the six months ended June 30, 2025 was $11.4 million, a significant improvement from $29.9 million in the same period last year.
Cash, cash equivalents, and marketable securities totaled $95.6 million as of June 30, 2025, expected to fund operations for at least 12 months if the merger is not consummated.
Company’s future operations are highly dependent on successful completion of the merger or another strategic transaction.
Financial highlights
Net loss for Q2 2025 was $2.8 million, compared to $13.8 million in Q2 2024; six-month net loss was $11.4 million, down from $29.9 million year-over-year.
Operating expenses for the six months ended June 30, 2025 decreased 43% year-over-year to $19.5 million, driven by lower R&D and G&A costs.
Research and development expenses fell 60% year-over-year to $7.7 million for the six months ended June 30, 2025.
General and administrative expenses decreased 11% year-over-year to $10.1 million for the six months ended June 30, 2025.
Other income for the six months ended June 30, 2025 was $8.2 million, including $4.3 million in R&D reimbursements and $0.8 million in sublease income.
Outlook and guidance
If the merger closes, the combined company will focus on advancing Inmagene’s lead candidate, IMG-007, in atopic dermatitis and other immunology indications.
If the merger or another strategic transaction is not completed, the board may pursue dissolution and liquidation, with cash available for distribution dependent on timing and liabilities.
Ongoing costs expected for merger-related activities and strategic review; additional funding may be needed if development resumes.
What is the post-merger R&D focus?
What is the liquidity outlook if merger fails?
What drove the Q2 2025 'Other Income' increase?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ikena Oncology earnings date
Q3 20256 Nov, 2025
Next Ikena Oncology earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ikena Oncology is a U.S.-based biopharmaceutical company focused on developing innovative therapies targeting cancer and other immune-related diseases. The company's research centers on molecular mechanisms that drive tumor growth and immune evasion, with a focus on precision oncology and immuno-oncology approaches. Ikena’s pipeline includes treatments aimed at targeting key signaling pathways involved in cancer progression, with therapies designed to offer new options for patients with difficult-to-treat cancers. The company is headquartered in Boston, Massachusetts, and its shares are listed on NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage